Delhi High Court Shields 'ORSL' Maker from FSSAI's ORS Trademark Ban, Citing Due Process Concerns

NEW DELHI – In a significant interim order, the Delhi High Court has provided a protective shield to JNTL Consumer Health (India) Pvt. Ltd., the manufacturer of the popular hydration drink 'ORSL', restraining the Food Safety and Standards Authority of India (FSSAI) from enforcing a recent, sweeping ban on the use of the term "ORS" in beverage trademarks. The decision by Justice Sachin Datta underscores critical principles of administrative law and procedural fairness, setting the stage for a high-stakes legal battle at the intersection of public health, intellectual property, and regulatory power.

The Court's intervention comes in response to a writ petition filed by JNTL challenging two FSSAI orders, dated October 14 and 15, 2025, which abruptly prohibited food and beverage companies from using "ORS" (Oral Rehydration Solution) in their product names, labels, or trademarks, even as a prefix or suffix. Justice Datta directed that these orders "shall not be given effect to, qua the petitioner" until FSSAI decides on JNTL's representation after affording the company a proper hearing. This temporary reprieve effectively halts any potential coercive action against JNTL, including product seizures or license suspensions, which the company argued would cause irreparable financial and reputational harm.

The Regulatory Reversal and JNTL's Legal Challenge

The core of JNTL's petition, JNTL Consumer Health (India) Pvt. Ltd v. Union of India , challenges the FSSAI's sudden reversal of its own established policy. The FSSAI's October directive was a stark departure from its previous orders dated July 14, 2022, and February 2, 2024. Those earlier communications had permitted food business operators with registered trademarks containing "ORS" to continue their use, provided they included a clear disclaimer stating that the product was not a WHO-recommended Oral Rehydration Salts formulation.

JNTL argued that it had diligently complied with these prior directions, building its business and supply chain around this regulatory framework. The company contended that the FSSAI's sudden withdrawal of these approvals was executed without any prior notice, stakeholder consultation, or hearing, constituting a clear violation of natural justice.

The petition highlighted several key legal arguments: * Violation of Due Process: The unilateral decision contravenes the Food Safety and Standards Act, 2006, and its associated rules, which mandate a consultative process. * Breach of Judicial Precedent: The action disregards a 2021 Delhi High Court order in Rupa Singh v. Union of India , which specifically required FSSAI to engage in stakeholder consultations before taking adverse measures on this issue. * Conflict with Trademark Law: JNTL pointed to the opinion of the Controller General of Patents, Designs and Trademarks, which affirmed that terms like "ORS" could legitimately form part of a composite trademark under Section 17 of the Trade Marks Act, 1999. The company argued that FSSAI's earlier stance, which aligned with this view and was accepted before the Telangana High Court, was binding and could not be arbitrarily reversed.

JNTL underscored the severe commercial ramifications of the FSSAI's order, noting that products worth approximately ₹155–180 crore were already in the supply chain. The company claimed the abrupt ban exposed it to significant financial losses and risked eroding the brand equity and goodwill of 'ORSL', cultivated over two decades.

The Public Health Imperative Behind FSSAI's Ban

The FSSAI's contentious directive was not issued in a vacuum. It was the culmination of an eight-year-long public health advocacy campaign spearheaded by Hyderabad-based paediatrician Dr. Sivaranjani Santosh. Her efforts brought national attention to the potential dangers of commercially available, high-sugar electrolyte drinks being confused with the life-saving WHO-prescribed Oral Rehydration Salts.

Diarrhoea remains a leading cause of mortality among young children in India, and the WHO-ORS formula is a cornerstone of its treatment, hailed as one of the 20th century's greatest public health innovations. Dr. Santosh's campaign argued that beverage companies were creating a "dangerous trend" by marketing products with names like ORSL, which could mislead parents into using them for dehydrated children.

According to her research and public statements, many of these drinks contained dangerously low electrolyte levels and up to ten times more sugar than the medically recommended WHO formula. High sugar content can exacerbate diarrhoea, worsening dehydration rather than alleviating it. Dr. Santosh argued that the previously mandated disclaimers were often printed in minuscule font, failing to adequately inform consumers, particularly those in rural areas or with low literacy.

Her relentless advocacy, which included a Public Interest Litigation (PIL) in the Telangana High Court in September 2024, ultimately prompted FSSAI to issue the stringent October 14, 2025, advisory. The advisory unequivocally stated: “No drink, carbonated beverage, or food product shall carry ‘ORS’ on its label or trademark, with or without a prefix or suffix. Any such product is to be removed from sale immediately.”

Legal Analysis: A Clash of Competing Interests

The Delhi High Court's interim order does not rule on the merits of either FSSAI's public health concerns or JNTL's trademark rights. Instead, it focuses squarely on the procedural propriety of the regulator's actions. The order rests on the fundamental administrative law principle of audi alteram partem – the right to be heard.

By directing FSSAI to reconsider its position after a formal hearing, the Court has reinforced that even well-intentioned regulatory actions must adhere to due process. Regulators cannot reverse established policies, particularly those upon which businesses have relied, without providing affected parties an opportunity to present their case.

The case presents a fascinating legal dilemma: 1. Administrative Fairness vs. Public Safety: How does the judiciary balance the need for procedural fairness for corporations with a regulator's urgent mandate to protect public health from perceived consumer deception? 2. Intellectual Property vs. Generic Terms: When does a term with a specific medical or generic meaning ("ORS") become so integral to a brand's identity ('ORSL') that it gains protection under trademark law, and at what point does that protection conflict with public interest? 3. Regulatory Estoppel: Can a regulator be prevented from changing its policy (under the doctrine of promissory or regulatory estoppel) when new evidence or heightened public health concerns emerge?

The final outcome will have significant implications. A ruling in favour of FSSAI could embolden the regulator to take stricter measures against products with potentially misleading health-related branding. Conversely, a definitive win for JNTL could strengthen the position of trademark holders against regulatory overreach, reinforcing that intellectual property rights cannot be summarily curtailed without following a legally sound process.

For now, the High Court’s intervention ensures that the dispute will be resolved through a structured legal and administrative process, rather than a unilateral regulatory decree. All eyes will be on FSSAI's upcoming review and the subsequent hearing, which will determine the future of the 'ORSL' brand and set a crucial precedent for food and beverage regulation in India.